|
Enhancing T Cell Therapy of Cancer
|
5P01CA094237-13
|
$1,932,287
|
$483,072
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Localization and Function of NKT Cells in Neuroblastoma
|
5R01CA116548-10
|
$234,457
|
$234,457
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
2P30CA125123-09
|
$3,155,163
|
$189,310
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-09S2
|
$112,151
|
$6,729
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-09S3
|
$183,048
|
$10,983
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeting the G-CSF/STAT3 signaling pathway in neuroblastoma cancer stem cells
|
5R01CA174808-02
|
$326,348
|
$326,348
|
SHOHET, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Role of Growth Factor Receptor Trafficking in Tumorigenesis
|
3R01CA166749-03S1
|
$65,036
|
$65,036
|
ZAGE, PETER
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Role of Growth Factor Receptor Trafficking in Tumorigenesis
|
5R01CA166749-03
|
$318,913
|
$318,913
|
ZAGE, PETER
|
BAYLOR COLLEGE OF MEDICINE
|
|
Engineering a supramolecular platinum nanoparticle for pediatric cancer
|
5R21CA186009-02
|
$181,037
|
$90,519
|
SENGUPTA, SHILADITYA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S1
|
|
$0
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S2
|
$64,741
|
$5,179
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S3
|
$229,232
|
$18,339
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S4
|
$593,811
|
$47,505
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S5
|
$917,771
|
$73,422
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S6
|
$68,356
|
$5,468
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S7
|
$778,576
|
$62,286
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S8
|
$73,651
|
$5,892
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-02
|
$400,000
|
$80,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-02
|
$24,080,302
|
$1,926,424
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Role of LMO1 in Neuroblastoma Initiation and Maintenance
|
1R01CA180692-01A1
|
$623,838
|
$623,838
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Pediatric Preclinical Testing Consortium
|
1U01CA199287-01
|
$357,000
|
$357,000
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
The Genetic Basis of Neuroblastoma Tumorigenesis
|
5R01CA124709-08
|
$614,290
|
$614,290
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Targeting Oncogenic ALK Signaling in Neuroblastoma
|
5R01CA140198-07
|
$378,479
|
$378,479
|
MOSSE, YAEL
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Exploring the oncogenic potential of human APOBEC3 cytosine deaminases
|
1R21CA185799-01A1
|
$182,700
|
$62,118
|
WEITZMAN, MATTHEW
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma
|
5R01CA182633-02
|
$671,686
|
$671,686
|
ASGHARZADEH, SHAHAB
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Plasminogen activator inhibitor-1 in tumor progression and metastasis
|
5R01CA129377-08
|
$239,246
|
$239,246
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Center for Environment-Mediated Drug Resistance in Pediatric Cancer
|
5U54CA163117-05
|
$654,642
|
$477,889
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
National Center: Multiscale Analysis of Genomic and Cellular Networks (MAGNet)
|
3U54CA121852-10S1
|
$100,000
|
$8,000
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Systems Biology of Tumor Progression and Drug Resistance
|
5U01CA168426-04
|
$1,232,072
|
$1,232,072
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S1
|
$120,000
|
$4,800
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S2
|
$60,000
|
$2,400
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S3
|
$125,000
|
$5,000
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S4
|
$157,133
|
$6,285
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-41
|
$3,792,720
|
$151,709
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
HAUSP inhibitors in p53-wild type and p53-mutant tumors
|
1R01CA193890-01
|
$366,000
|
$91,500
|
GU, WEI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
3R01CA148688-05S1
|
$114,997
|
$114,997
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
5R01CA148688-05
|
$363,125
|
$363,125
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Uncovering the anti-apoptotic mechanism of mutated ALK in neuroblastoma
|
5F32CA183566-02
|
$54,194
|
$54,194
|
MOORE, NATHAN
|
DANA-FARBER CANCER INST
|
|
Epigenetic Regulation of Neuroblast Differentiation
|
1F31CA192558-01
|
$33,544
|
$33,544
|
GAVIGLIO, ANGELA
|
DUKE UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-07S1
|
$37,430
|
$374
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
5P30CA138292-07
|
$1,560,000
|
$15,600
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Regulation of MDM2 auto-ubiquitination and molecular targeting
|
5R01CA123490-08
|
$251,191
|
$62,798
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
Berberine downregulates MDM2 by interaction with DAXX in cancer cells
|
5R01CA143107-06
|
$237,269
|
$118,635
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
EORTC HEADQUARTERS
|
5U10CA011488-45
|
$250,025
|
$5,001
|
LACOMBE, DENIS
|
EUROPEAN ORG/RES/TREATMENT/CANCER
|
|
Employing the Myc Transcriptional Network to Reveal Oncogenic Pathways
|
5R01CA057138-24
|
$636,692
|
$318,346
|
EISENMAN, ROBERT
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Neuropeptide Y (NPY) as a hypoxia-driven metastatic factor
|
1R01CA197964-01
|
$350,628
|
$175,314
|
KITLINSKA, JOANNA
|
GEORGETOWN UNIVERSITY
|
|
Prenatal stress and neuroblastoma development - is there a link?
|
1R21CA198698-01
|
$202,928
|
$202,928
|
KITLINSKA, JOANNA
|
GEORGETOWN UNIVERSITY
|
|
Georgetown University Lombardi Cancer Center Support Grant
|
3P30CA051008-22S1
|
$31,250
|
$938
|
WEINER, LOUIS
|
GEORGETOWN UNIVERSITY
|
|
Georgetown University Lombardi Cancer Center Support Grant
|
5P30CA051008-22
|
$2,246,754
|
$67,403
|
WEINER, LOUIS
|
GEORGETOWN UNIVERSITY
|
|
Molecular determinants of PARP inhibitor sensitivity in 11q-deleted malignancy
|
1R21CA181417-01A1
|
$184,515
|
$92,258
|
FRANCO, SONIA
|
JOHNS HOPKINS UNIVERSITY
|
Total relevant funding to Neuroblastoma for this search: $19,155,625
|